KRAS and cancer: The concordance rate of KRAS mutations between cancer gene panel testing by NGS using ROSE specimens and KRAS mutation analysis by the Scorpion-ARMS or PCR-rSSO method using residual materials was 81% (21/26) (Fig 3).